16 material Form 8-K filings that 14 companies we cover made with the SEC in June 2023, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Galata Acquisition Corp., a blank check company, said its June 22, 2023 proxy statement/prospectus understated the estimated redemption value per Class A ordinary share, which is $10.46 rather than $10.26. It extended the deadline for holders to elect redemption from June 30 to July 5, 2023, ahead of the July 5 extraordinary general meeting that will consider its proposed business combination with Marti Technologies Inc.
Estimated redemption value per Class A ordinary share revised to $10.46 from $10.26, based on trust account marketable securities as of March 31, 2023
Redemption deadline moved from 5:00 p.m. New York City time on June 30, 2023 to 5:00 p.m. on July 5, 2023
Meeting to open July 5, 2023 at 10:00 a.m. Eastern Time and adjourn to July 6, 2023 at 10:00 a.m.
Company anticipates closing the Marti transaction in the third quarter of 2023
National Beverage reported results for the fourth quarter and fiscal year ended April 29, 2023. Fourth-quarter net sales rose to a record $287 million and net income increased 6% to $36 million, while fiscal-year net sales reached a record $1.2 billion with net income of $142 million. Both headline measures improved over the prior year, and the company said gross margin grew to 36% of sales.
Q4 net sales $286.7 million vs. $284.2 million a year earlier; net income $36.3 million vs. $34.3 million
Fiscal-year net sales increased $35 million to a record $1.2 billion; net income $142 million; diluted EPS $1.52
Fiscal-year net cash from operations was $162 million
Vicor's stockholders re-elected all twelve director nominees at the June 23, 2023 annual meeting and approved, on an advisory basis, the compensation of named executive officers. Stockholders also voted for advisory votes on executive pay every three years, which the Board adopted as policy. The filing also discloses the annual director stock option grant, now sized at $200,000 per director rather than $100,000.
All twelve director nominees were elected to serve until the 2024 annual meeting; Patrizio Vinciarelli received 135,823,033 votes for and 6,912,058 withheld.
Say-on-pay proposal passed with 141,019,623 votes for, 1,119,558 against and 595,910 abstaining.
Stockholders chose a three-year frequency for advisory executive compensation votes; the Board adopted this policy.
Directors received options on 3,769 shares at $53.07 per share, with the grant formula changed from $100,000 to $200,000 of value.
Graco said its President of the Electric Motor Division and a named executive officer, Jeffrey P. Johnson, told the company on June 16, 2023 that he intends to retire effective December 31, 2023. The filing does not name a successor or describe any change to his compensation.
Jeffrey P. Johnson, President, Electric Motor Division, informed Graco of his retirement intention on June 16, 2023.
Retirement is effective December 31, 2023.
The filing does not name a successor or describe compensation changes.
Effective immediately, David Hammer and Kyle Christine are primarily responsible for the day-to-day management of PIMCO California Municipal Income Fund (PCQ). The filing describes their backgrounds, including Hammer's prior roles at PIMCO and Morgan Stanley and Christine's time at Morgan Stanley before joining PIMCO in 2017.
Effective immediately, Hammer and Christine are primarily responsible for day-to-day management of the fund
David Hammer is a Managing Director and municipal bond portfolio manager in the Newport Beach office; he rejoined PIMCO in 2015
Kyle Christine is a Senior Vice President and municipal bond portfolio manager in the Newport Beach office; he joined PIMCO in 2017
Effective immediately, David Hammer and Kyle Christine are primarily responsible for the day-to-day management of the fund, according to an 8-K filed June 16, 2023. The filing provides biographical details for both managers, both of whom are municipal bond portfolio managers in PIMCO's Newport Beach office.
David Hammer is a Managing Director and municipal bond portfolio manager; he rejoined PIMCO in 2015 from Morgan Stanley.
Kyle Christine is a Senior Vice President and municipal bond portfolio manager; he joined PIMCO in 2017 from Morgan Stanley.
The change took effect immediately, as stated in the filing dated June 16, 2023.
PIMCO Municipal Income Fund II said that, effective immediately, David Hammer and Kyle Christine are primarily responsible for the fund's day-to-day management. The filing provides biographical details for both portfolio managers but does not describe any change in fund strategy, fees, or portfolio.
Effective immediately as of the June 16, 2023 filing, David Hammer and Kyle Christine are primarily responsible for day-to-day management.
David Hammer is a Managing Director and municipal bond portfolio manager in the Newport Beach office; he rejoined PIMCO in 2015 from Morgan Stanley.
Kyle Christine is a Senior Vice President and municipal bond portfolio manager in the Newport Beach office; he joined PIMCO in 2017 from Morgan Stanley.
Chemomab Therapeutics appointed Sigal Fattal, its former VP of Finance, as Chief Financial Officer on June 1, 2023, and the Board approved her compensation on June 14, 2023. The package includes a $260,000 base salary, a bonus potential of 45% of base salary tied to objectives yet to be set, and options on 102,860 ADSs at $1.70 that vest over four years.
Appointed Sigal Fattal as Chief Financial Officer on June 1, 2023; she previously served as VP of Finance
Annual base salary of $260,000, plus a bonus potential of 45% of base salary
Options to buy 102,860 American Depositary Shares at $1.70, vesting over four years, with acceleration on a change in control
Kayne Anderson Energy Infrastructure Fund (KYN) and Kayne Anderson NextGen Energy & Infrastructure (KMF) have a definitive agreement to combine the two funds, subject to stockholder approval. The funds reset the record date to June 20, 2023, so holders of record on that date can vote at the special meeting. The filing does not give a meeting date; a definitive joint proxy statement will follow after an SEC review period.
Merger agreement dated April 24, 2023, as amended and restated, between KYN and KMF
Stockholders of record as of close of business June 20, 2023 may vote on the Merger
Definitive joint proxy statement/prospectus, including the special meeting date, to be mailed after SEC review
EUDA Health Holdings said Nasdaq told it on June 13, 2023 that it regained compliance with Listing Rule 5635(c) after CEO Dr. Kelvin Chen agreed to forfeit 271,867 of 850,306 shares issued to him in a loan settlement. Separately, Nasdaq accepted the company's plan to regain compliance with its late-filing rule, provided it files overdue reports by August 4, 2023, or faces possible delisting.
Chen received 850,306 restricted shares at $1.00 each to settle $850,306 in loans; the issue was priced below the $1.47 prior closing bid, which required shareholder approval.
Under a June 8, 2023 Supplemental Agreement, Chen forfeited 271,867 shares, leaving an effective issue price of $1.47 per share.
The company must file its delinquent 10-K and 10-Q by August 4, 2023; failure could lead to a delisting notice and appeal to a Nasdaq Hearings Panel.
PC Connection entered into a Fourth Amendment to its credit agreement with Citizens Bank, N.A. on June 13, 2023, under which the company may borrow up to $50.0 million, with an option to increase that to $80.0 million in certain circumstances. The amendment mainly replaces LIBOR-based references with the BSBY Rate and related loan terms, and the filing does not describe changes to borrowing limits or financial covenants.
Amendment dated June 13, 2023, with Citizens Bank, N.A. as agent and lender
Credit facility allows borrowing up to $50.0 million, expandable to $80.0 million at the company's option in certain circumstances
'LIBOR Rate' references replaced with 'BSBY Rate', defined with a 0.00% floor
EUDA amended its prepaid forward agreements with institutional investors on June 8, 2023, accelerating the maturity date. As a result, 1.6 million ordinary shares became immediately due to the sellers, and the sellers became entitled to retain the remaining prepayment from the trust account and the remaining shares. The share issuance adds to the existing share count and could dilute current shareholders, and the filing also reports a board change and a revised settlement with CEO Dr. Kelvin Chen.
1.6 million ordinary shares issuable as Maturity Consideration, 800,000 to each of two sellers, HB Strategies LLC and Alto Opportunity Master Fund, SPC
Maturity Date accelerated to June 8, 2023; the sellers may retain the remaining prepayment from EUDA's trust account and remaining shares
Sellers received registration rights and may not sell more than 15% of the daily trading volume on any exchange business day
Alfred Lim was appointed Executive Director on June 6, 2023 and resigned from three board committee roles
On June 4, 2023, BiondVax Pharmaceuticals Ltd., which trades as SCNI, entered an exclusive worldwide license to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) from Max-Planck-Innovation GmbH and University Medical Center Gottingen. The company agreed to issue 17,000 American Depository Shares to the counterparties and to owe milestone payments and royalties on net sales, and the license will terminate if an IND is not submitted by the stated deadlines.
17,000 American Depository Shares to be issued to the counterparties within 45 days of June 4, 2023
Recipients agreed not to sell the ADSs until June 4, 2024
IND submission deadline of June 30, 2025, with a possible extension of 12 months per EUR 500,000 payment
License terminates prior to December 31, 2026 if the IND deadline is not met
High Income Securities Fund (PCF), Bulldog Investors LLP and Special Opportunities Fund, Inc. (SPE) announced on May 11, 2023 that they filed an action in the U.S. District Court for the District of Massachusetts. The suit concerns the April 3, 2023 annual meeting of First Trust Dynamic Europe Equity Income Fund (FDEU) and seeks to enforce votes for SPE's nominees to its Board of Trustees. The filing does not state any direct financial effect on PCF shareholders.
Action filed in the U.S. District Court for the District of Massachusetts; announced May 11, 2023
Seeks a declaration that SPE's nominees received a majority of votes that would have been cast had the FDEU board counted them
Also seeks a declaration that FDEU's control share bylaw violates the Investment Company Act of 1940 and is invalid
Morris Kandinov LLP is serving as counsel to Bulldog, SPE and PCF
Special Opportunities Fund, Bulldog Investors LLP and High Income Securities Fund filed a lawsuit in the U.S. District Court for the District of Massachusetts over the April 3, 2023 annual meeting of First Trust Dynamic Europe Equity Income Fund (FDEU). The action seeks to enforce votes for the Fund's nominees to FDEU's Board of Trustees, which the plaintiffs say the incumbent board improperly refused to count. The filing discloses the litigation but does not give a financial result for the Fund.
The press release announcing the lawsuit is dated May 11, 2023 and is attached as Exhibit 99.1.
The lawsuit seeks a declaration that the Fund's nominees received a majority of the votes that would have been cast but for the incumbent board's refusal to count them.
The lawsuit also asks the court to declare FDEU's control share bylaw, which limits voting rights beyond certain ownership thresholds, invalid under the Investment Company Act of 1940.
Chemomab Therapeutics replaced CEO Dale Pfost and CFO Donald Marvin effective June 1, 2023, reappointing co-founder Adi Mor as CEO and Sigal Fattal as CFO, and named Nissim Darvish Chairman. The company also said it is implementing further cost-reduction measures to extend its cash runway to the end of 2024 and is suspending initiation of a Phase 2 systemic sclerosis trial to preserve capital.
Adi Mor appointed CEO effective June 1, 2023; her compensation will be set later and subject to shareholder approval
Sigal Fattal appointed CFO, replacing Donald Marvin, effective June 1, 2023
Cash runway expected to extend from mid-year 2024 to end of 2024, after the Phase 2 PSC topline data readout expected in the latter part of 2024
Former CEO Dale Pfost will receive 12 months of base salary in cash, accelerated stock option vesting and 12 months of COBRA premiums, subject to a separation agreement
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.